TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19492250

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in TOF patients at rest
Number of subjects: 20

Group type: COMPARATOR
Intervention: NT-proBNP level in control healthy children at rest
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in TOF patients repaired with transannular patch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in TOF patients operated on without transannular patch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in children with physiological shortening of QRS complex during treadmill test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP level in patients with prolongation of QRS duration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in children with severe pulmonary regurgitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: NT-proBNP levels in children with mild/moderate pulmonary regurgitation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in children with severe tricuspid valve insufficiency
Number of subjects: 20

Group type: COMPARATOR
Intervention: NT-proBNP levels in children with mild/moderate tricuspid valve regurgitation
Number of subjects: 20
Study: 17366867

Group type: EXPERIMENTAL
Intervention: Peritoneal drainage at the conclusion of surgery (GI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No drainage applied (GII)
Number of subjects: 23
Study: 15330896

Group type: EXPERIMENTAL
Intervention: Intake of a standard meal within 5 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intake of a standard meal within 30 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: First postprandial hour
Number of subjects: 20

Group type: COMPARATOR
Intervention: Second postprandial hour
Number of subjects: 20
Study: 11108723

Group type: EXPERIMENTAL
Intervention: Olive oil diet (50 g of oil per 10 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rapeseed oil diet (50 g of oil per 10 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sunflower oil diet (50 g of oil per 10 MJ)
Number of subjects: 18
Study: 11763909

Group type: EXPERIMENTAL
Intervention: Essential oil dentifrices
Number of subjects: 170

Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 170
Study: 8707743

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 17
Study: 1520191

Group type: EXPERIMENTAL
Intervention: Ambulation in the first stage and squatting position during the second stage of labour
Number of subjects: 200

Group type: COMPARATOR
Intervention: Supine position throughout labour
Number of subjects: 200
Study: 6240210

Group type: EXPERIMENTAL
Intervention: atracurium (ATR) 0.33 mg X kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alcuronium (DAN) 0.1 mg X kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: succinylcholine (SCH) 1.0 mg X kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: atracurium (ATR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alcuronium (DAN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: atracurium (ATR) and alcuronium (DAN)
Number of subjects: 40
Study: 30044792

Group type: EXPERIMENTAL
Intervention: Anfoleish cream administered 2 times per day (BID group) for 4 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anfoleish cream administered 3 times per day (TID group) for 4 weeks
Number of subjects: 80
Study: 26823689

Group type: EXPERIMENTAL
Intervention: seCPT (cold water)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control (warm water)
Number of subjects: 232
Study: 25546691

Group type: EXPERIMENTAL
Intervention: In-plane ultrasound-guided injection with 40 mg of triamcinolone and 1 mL of 1% lidocaine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Out-plane ultrasound-guided injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Blind injection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In-plane ultrasound-guided injection
Number of subjects: 44
Study: 23223698

Group type: EXPERIMENTAL
Intervention: Exercise Group (n = 50) - quadriceps strengthening exercises, stationary bicycle, hamstrings stretching
Number of subjects: 100

Group type: COMPARATOR
Intervention: Instruction Group (n = 50) - manual with information about knee osteoarthritis
Number of subjects: 100
Study: 19716742

Group type: EXPERIMENTAL
Intervention: Specific neck/shoulder resistance training
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: All-round physical exercise
Number of subjects: 549

Group type: COMPARATOR
Intervention: Reference intervention
Number of subjects: 549
Study: 17414691

Group type: EXPERIMENTAL
Intervention: Open-label, flexible-dose antidepressant treatment for 8 weeks
Number of subjects: 454
Study: 15819755

Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 11931781

Group type: EXPERIMENTAL
Intervention: Regimen A (3 weekly injections as induction, followed by injections every 2 weeks)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Regimen B (two injections at day 1 and day 15 as induction, followed by injections every 4 weeks)
Number of subjects: 93
Study: 9536858

Group type: EXPERIMENTAL
Intervention: Triacylglycerols rich in palmitic acid at the sn-2 position
Number of subjects: 8

Group type: COMPARATOR
Intervention: Triacylglycerols rich in palmitic acid at the sn-1,3 positions
Number of subjects: 8
Study: 7632972

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) after autologous BMT
Number of subjects: 135

Group type: COMPARATOR
Intervention: No Interleukin-2 (IL-2) after autologous BMT
Number of subjects: 135
Study: 2713221

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 28767453

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: IV fentanyl
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Penile block
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (caudal block vs IV fentanyl vs penile block)
Number of subjects: 31
Study: 30128810

Group type: EXPERIMENTAL
Intervention: Community organization partnerships
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Participant referrals
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Ethnic-based media announcements
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Community organization outreach
Number of subjects: 406
Study: 26797499

Group type: EXPERIMENTAL
Intervention: Urine lipoarabinomannan strip test (LAM)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Sputum smear microscopy (SSM)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: LAM and SSM combined
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: LAM
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: LAM or SSM alone or combined LAM and SSM
Number of subjects: 457
Study: 24513605

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21936720

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% citric acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: KTP laser at 1 W, 4.45 J/cm(2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 60
Study: 19325450

Group type: EXPERIMENTAL
Intervention: PHiD-CV coadministered with DTPa-HBV-IPV/Hib and MenC-CRM (Meningitec)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: PHiD-CV coadministered with DTPa-HBV-IPV/Hib and MenC-TT (NeisVac-C)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: PHiD-CV coadministered with DTPa-HBV-IPV and Hib-MenC-TT (Menitorix)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: 7vCRM (Prevenar/Prevnar) coadministered with DTPa-HBV-IPV and Hib-MenC-TT
Number of subjects: 1548
Study: 18628653

Group type: EXPERIMENTAL
Intervention: Progressive upper-body resistance training (RT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (UC) aerobic exercise
Number of subjects: 30
Study: 16463664

Group type: EXPERIMENTAL
Intervention: Risedronate sodium
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12898884

Group type: COMPARATOR
Intervention: IL-18 serum concentration measurement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Flow cytometry analysis
Number of subjects: 14
Study: 10357990

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol dissolved in acetic acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: 200 microg misoprostol dissolved in water
Number of subjects: 120
Study: 7856825

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadoxine (Fansidar)
Number of subjects: 0
Study: 2020921

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (600 mg)
Number of subjects: 12
Study: 7126418

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (100 mg/day) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (100 mg/day) with spironolactone (100 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapies (Hydrochlorothiazide and spironolactone)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg/day) once daily
Number of subjects: 12
Study: 31151464

Group type: EXPERIMENTAL
Intervention: Oral taurine supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Weight-loss diet
Number of subjects: 50
Study: 28012528

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.5 mg/kg (maximum dose 16 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Pre‐incision infiltration of local anesthesia (2-4 ml mixture with saline)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.5 mg/kg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Pre‐incision infiltration of local anesthesia
Number of subjects: 129
Study: 25612858

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g every 24 hours for 4 days)
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Standard stroke unit care (control group)
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2538
Study: 23607755

Group type: EXPERIMENTAL
Intervention: Early intervention group (trained nurses providing brief lifestyle intervention)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Late intervention group (usual care for first 6 months, then training)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Both groups (early and late intervention)
Number of subjects: 804
Study: 21296446

Group type: EXPERIMENTAL
Intervention: Yoptimal (10^9 cfu/100g of BB-12 and LA-5 and 40mg of green tea extract)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Yoptimal-10 (10^10 cfu/100g of BB-12, 10^9 cfu/100g of LA-5 and 40mg of green tea extract)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (no probiotic, no starter and no green tea extract)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 19665347

Group type: EXPERIMENTAL
Intervention: MI pretreatment (Motivational Interviewing)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MI-CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No pretreatment (NPT)
Number of subjects: 76
Study: 17465500

Group type: EXPERIMENTAL
Intervention: 5 granulocyteaphaeresis sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 granulocyteaphaeresis sessions
Number of subjects: 20
Study: 14969576

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11467142

Group type: EXPERIMENTAL
Intervention: 2-site regimen (0.2 ml at 2 sites on days 0, 3, 7; 1 site on days 28, 90)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 8-site regimen (0.1 ml at 8 sites on day 0; 4 sites on day 7; 1 site on days 28, 90)
Number of subjects: 82
Study: 9747644

Group type: EXPERIMENTAL
Intervention: Plantago Psyllium (5 g t.i.d.)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 7600397

Group type: EXPERIMENTAL
Intervention: Intraoral approach
Number of subjects: 12

Group type: COMPARATOR
Intervention: Percutaneous approach
Number of subjects: 12
Study: 2848604

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20
Study: 30251879

Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia-Hyperoxia Training (IHHT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 32
Study: 27282835

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) (4 × 5 min 220 mm Hg unilateral occlusion)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control intervention (no RIPC)
Number of subjects: 25
Study: 24700256

Group type: EXPERIMENTAL
Intervention: Normothermic LBNP tolerance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperthermic LBNP tolerance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperthermic LBNP tolerance in HIGH group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperthermic LBNP tolerance in LOW group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of HIGH and LOW groups under hyperthermia
Number of subjects: 60
Study: 23587533

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study: 20547600

Group type: EXPERIMENTAL
Intervention: Sodium salicylate injections into tender, thickened areas of subcutaneous tissue on the forearm and upper scapular region.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham injections consisting of pressure without skin penetration.
Number of subjects: 40
Study: 18400140

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg kg(‐1) administered intravenously over 60 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 mL of 0.9% NaCl administered intravenously over 60 s (Control Group)
Number of subjects: 40
Study: 15746991

Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11955844

Group type: EXPERIMENTAL
Intervention: Double the ACE inhibitor dose (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Add an angiotensin II antagonist (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (n = 10)
Number of subjects: 30
Study: 10206072

Group type: EXPERIMENTAL
Intervention: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen for four 3‐weekly cycles
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-treatment control group (20 patients)
Number of subjects: 31
Study: 7783715

Group type: EXPERIMENTAL
Intervention: Adhesive tape applied over a pectin-based barrier
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adhesive tape applied directly to the skin
Number of subjects: 20
Study: 2079058

Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.5 g.kg‐1 body mass
Number of subjects: 0
Study: 7418568

Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-weekly regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily regimen of isoniazid (INH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-weekly regimen of rifampicin (RMP)
Number of subjects: 0
Study: 31660609

Group type: EXPERIMENTAL
Intervention: Advance care planning video offered to black residents
Number of subjects: 43303

Group type: EXPERIMENTAL
Intervention: Advance care planning video shown to black residents
Number of subjects: 43303

Group type: COMPARATOR
Intervention: Cognitive impairment
Number of subjects: 43303
Study: 31099866

Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 2114
Study: 28369299

Group type: EXPERIMENTAL
Intervention: Pentasa® enemas 25 mg/kg (up to 1g) daily for 3 weeks
Number of subjects: 38
Study: 25810322

Group type: EXPERIMENTAL
Intervention: Er:Glass fractional laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fractional radiofrequency microneedle device
Number of subjects: 40
Study: 22882430

Group type: EXPERIMENTAL
Intervention: Oral desensitization with raw hen's egg starting from 0.27 mg (1 drop diluted 1:100) and increasing doses over 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 20
Study: 20727238

Group type: EXPERIMENTAL
Intervention: Gold kiwifruit with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Number of subjects: 89

Group type: COMPARATOR
Intervention: Banana with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Number of subjects: 89
Study: 19576316

Group type: EXPERIMENTAL
Intervention: No flow-limiting stenosis
Number of subjects: 782

Group type: COMPARATOR
Intervention: > or =1 flow-limiting stenosis
Number of subjects: 782
Study: 17968434

Group type: EXPERIMENTAL
Intervention: Sibutramine with diet and exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study: 15447821

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 37
Study: 11447381

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg, 25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study: 9738560

Group type: EXPERIMENTAL
Intervention: GM-CSF at 5 microg/kg/d
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (antibiotics only)
Number of subjects: 68
Study: 8039407

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 38000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38000
Study: 2975612

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30223903

Group type: EXPERIMENTAL
Intervention: Blended GP educational programme (online and face-to-face training) with proactive discussion of pain management and prescription of paracetamol and ibuprofen according to guidelines.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 250
Study: 27194622

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 20234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20234
Study: 25771087

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) administered subcutaneously
Number of subjects: 69

Group type: COMPARATOR
Intervention: Acenocoumarol (Vitamin K antagonist)
Number of subjects: 69
Study: 23064902

Group type: EXPERIMENTAL
Intervention: Glutamine (15 g orally, three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0
Study: 21474134

Group type: EXPERIMENTAL
Intervention: Laparoscopic bipolar electrocoagulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Laparotomic hemostatic sutures
Number of subjects: 59
Study: 18341663

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 121
Study: 17065974

Group type: EXPERIMENTAL
Intervention: Antidepressant selection based on drug factors (tolerability, interactions, cost), depression subtype, psychiatric and medical comorbidity, and stage of life.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preference for avoiding certain side effects and personal and family history of treatment response.
Number of subjects: 0
Study: 12945061

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diaphragmatic Breathing (DB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 35
Study: 11121910

Group type: EXPERIMENTAL
Intervention: 5-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Number of subjects: 139

Group type: COMPARATOR
Intervention: 7-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Number of subjects: 139
Study: 9085405

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 26
Study: 1350367

Group type: EXPERIMENTAL
Intervention: 100 micrograms of salmeterol
Number of subjects: 19

Group type: COMPARATOR
Intervention: 40 mg of sodium cromoglycate
Number of subjects: 19
Study: 3553247

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate in optimized vehicle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clobetasol‐17‐propionate ointment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both drugs (Betamethasone and Clobetasol)
Number of subjects: 40
Study: 29222596

Group type: EXPERIMENTAL
Intervention: Cold water bath (3 °C) for 20 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neutral water bath (32 °C) for 10 minutes
Number of subjects: 20
Study: 27998265

Group type: EXPERIMENTAL
Intervention: Participatory intervention (workshops with leaders and selected healthcare workers)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Control group (13 clusters, 318 healthcare workers)
Number of subjects: 642